S&P ups Teva view to stable

Standard & Poor's said it revised its outlook on Teva Pharmaceutical Industries Ltd. to stable from negative. Ratings, including the BBB corporate credit rating, were affirmed.

The company holds a broad position in the fragmented and competitive worldwide generic drug market, with a roughly 12% market share, S&P said.

However, the company has maintained a moderate financial profile, funding its acquisitions with a prudent mix of debt and equity and then quickly de-leveraging, the agency added.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.